2004 Volume 44 Issue 2 Pages 63-66
Fluid retention of more than 2kg, with no sign of pitting edema, was observed in 5 of 15 patients with refractory multiple myelomas treated by thalidomide. Cardiac function in all except one patient, who developed overt heart failure, were controlled well by diuretics. Median time from starting thalidomide to developing fluid retention was ten days (range 6 to 41 d). The fluid retention was transient in most patients, allowing thalidomide therapy to continue. However, when fluid retention could not be controlled by diuretics, thalidomide had to be discontinued. It is important that fluid retention is a significant adverse reaction to thalidomide therapy and that even overt heart failure can be obvious.